Dopaminergic agents were analyzed in the past for the treatment of RA, based on the fact that the stimulation of D2-like DR leads to the inhibition of prolactin, a proinflammatory hormone that is released by the anterior pituitary gland (McMurray 2001) and that is present at high concentration in the serum and synovial fluid of RA patients (Borba et al. 2018; Fojtikova et al. 2010). This evidence concerns the gene PRL and rheumatoid arthritis.